Terry Fry's guest appearances

Terry Fry

Charting Pediatrics

AESP Podcasts

John Barnard

David Hill

David Turner

Peter Hotez

Greg Walker

Ben Katz

Adam Green

Samantha Hill

Doug Scott

Stephen Scott

Brian Shaw

Bill Anderson

Julie Wilson

Josh Williams

Flaccid Myelitis

OwlTail

Michael Verneris

Cellular therapy is a new type of immunotherapy that is bringing hope to pediatric patients with blood cancers.  The therapy is more specifically known as chimeric antigen receptor T cell therapy (or CAR-T cell therapy), and it has been hailed as a breakthrough in the field of immunotherapy. CAR-T cell therapy "takes the brakes" off the immune system's response. Essentially, it trains the cells within the immune system, called T cells, to see tumors they weren't naturally developed to recognize. Two years ago, we had the brilliant team of  Terry Fry, MD and  Mike Verneris, MD join us to discuss this therapy for patients with leukemia and other cancers; you can go back and listen to that initial discussion on  Season 1, episode 33. We continue to hear from listeners how much they enjoyed this discussion of clinical invocation and application and decided that it was time to bring Dr. Fry and Dr. Verneris back to hear an update on their work and what the latest in the space of CAR-T cell therapy is.

Cellular therapy is a new type of immunotherapy that is bringing hope to pediatric patients with blood cancers.  The therapy is more specifically known as chimeric antigen receptor T cell therapy (or <a href="https://www.childrenscolorado.org/doctors-and-departments/departments/cancer-and-blood-disorders/programs/bone-marrow-transplant/car-t-cell-therapy-process/" rel="nofollow" target="_blank">CAR-T cell</a> therapy), and it has been hailed as a breakthrough in the field of immunotherapy. CAR-T cell therapy "takes the brakes" off the immune system's response. Essentially, it trains the cells within the immune system, called T cells, to see tumors they weren't naturally developed to recognize. Two years ago, we had the brilliant team of <a href="https://www.childrenscolorado.org/doctors-and-departments/physicians/f/terry-fry/" rel="nofollow" target="_blank"> Terry Fry, MD</a> and <a href="https://www.childrenscolorado.org/doctors-and-departments/physicians/v/michael-verneris/" rel="nofollow" target="_blank"> Mike Verneris, MD</a> join us to discuss this therapy for patients with leukemia and other cancers; you can go back and listen to that initial discussion on <a href="https://www.childrenscolorado.org/health-professionals/professional-resources/charting-pediatrics-podcast/car-t-cell-therapy-leukemia/" rel="nofollow" target="_blank"> Season 1, episode 33.</a> We continue to hear from listeners how much they enjoyed this discussion of clinical invocation and application and decided that it was time to bring Dr. Fry and Dr. Verneris back to hear an update on their work and what the latest in the space of CAR-T cell therapy is.

CAR-T Cellular Therapy: Advancing Pediatric Cancer Treatment with Terry Fry, MD and Michael Verneris, MD S3:E62

- The clean energy industries create three times as many jobs as the other fossil fuels combined, this is a fast growing industry-  Energy efficiency accounts for 2.2 million jobs in the US -  The certificate of excellence in DSM program management provides excellent training and create opportunities for individuals in the market

- The clean energy industries create three times as many jobs as the other fossil fuels combined, this is a fast growing industry - Energy efficiency accounts for 2.2 million jobs in the US - The certificate of excellence in DSM program management provides excellent training and create opportunities for individuals in the market

Terry Fry, Senior VP Cadmus